Biotechnology company Imugene (ASX:IMU) said a bile tract cancer patient in its phase 1 metastatic advanced solid tumors trial for Vaxinia, a treatment candidate for bile tract cancer, remained in complete response, surpassing over two years in remission, according to a Tuesday filing with the Australian bourse.
Meanwhile, the trial's bile tract cancer expansion phase cleared its first group, with the three patients experiencing no dose-limiting toxicities, and is now open for enrollment of up to 10 patients, the filing said.
The company also secured a patent extension to 2040 from the US Patent and Trademark Office for patent application number 16/324,541, protecting its oncolytic virotherapy CF33, including Vaxinia and CHECKVacc, according to the filing.
Imugene shares fell past 2% in morning trade Wednesday.
Price (AUD): $0.05, Change: $-0.001, Percent Change: -2.13%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。